Clarity AD CSF Substudy Findings on Lecanemab Treatment and α-Synuclein Co-Pathology Presented at CTAD 2026

The Quick Take
Lecanemab showed favorable results on clinical assessment scores at 18 months, including among individuals with early Alzheimer's disease (AD) who were α-synuclein positive, a subgroup associated with higher amyloid burden and faster clinical decline TOKYO and CAMBRIDGE, Mass., Nov. 19,...
Ground Level News aggregates headlines from public feeds. This page shows a short summary only; the full article and all rights belong to PR Newswire M&A.
Related
Business
Industry Leaders Across APAC and MEASA Gather in Singapore to Celebrate Frost & Sullivan's 65th Anniversary at Recognition Banquet
Recognizing organizations demonstrating outstanding best practices, innovation, leadership, and transformational growth across regional and global markets. SAN…
Business
Ellington Credit earnings missed by $0.05, revenue topped estimates
Business
Sinopec organiza un evento paralelo en el Pabellón de China de la COP31
- Sinopec organiza un evento paralelo en el Pabellón de China de la COP31 y publica perspectivas sobre energía y combustibles verdes ANTALYA, Turquía, 20 de…
Business
GTA 6 breaks records as sales top $2bn - industry estimate
Rockstar Games ended a 13-year wait with what is expected to be the biggest entertainment launch ever.
